

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/22	A1	(11) International Publication Number: WO 98/01128 (43) International Publication Date: 15 January 1998 (15.01.98)
(21) International Application Number: PCT/IT97/00113 (22) International Filing Date: 15 May 1997 (15.05.97) (30) Priority Data: RM96A000479 5 July 1996 (05.07.96) IT (71) Applicant (for all designated States except US): MENDES S.R.L. [IT/IT]; Via Catania, 1, I-00161 Roma (IT). (72) Inventor; and (75) Inventor/Applicant (for US only): DE SIMONE, Claudio [IT/IT]; Via Nuoro, 10, I-00040 Ardea (IT). (74) Agents: CAVATTONI, Fabio et al.; Cavattoni - Raimondi, Viale dei Parioli, 160, I-00197 Roma (IT).		(81) Designated States: CA, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: USE OF L-ACETYLCARNITINE, L-ISOVALERYLCARNITINE, L-PROPIONYLCARNITINE FOR INCREASING THE LEVELS OF IGF-1 (57) Abstract Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine or pharmacologically acceptable salts thereof for increasing the levels of IGF-1 for the therapeutic treatment or prophylaxis of cytological disorders or diseases related to IGF-1.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

USE OF L-ACETYLCARNITINE, L-ISOVALERYLCARNITINE, L-PROPIONYLCARNITINE FOR INCREASING THE LEVELS OF IGF-1

The present invention relates to a novel therapeutic use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine or pharmacologically acceptable salts thereof for increasing the levels of IGF-1 (insulin-like growth factor 1) for the therapeutic treatment or prophylaxis of cytological disorders or diseases related to IGF-1. More particularly, the present invention relates to the use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine or pharmacologically acceptable salts thereof for the therapeutic treatment or prophylaxis of individuals in whom IGF-1 contributes towards the pathogenesis of a particular disease or provokes cytological disorders.

Like other growth factors, IGF-1 promotes cell growth and differentiation. The administration of IGF-1 obtained as a protein purified by molecular biology methods has made it possible to confirm the effects observed *in vitro* with cells, on animal models and in man. Essentially, the action of IGF-1 is similar to that of insulin, that is to say an increase in the uptake of glucose, a reduction in ketones and fatty acids in the serum and an increase in protein synthesis. In accordance with these and other metabolic effects, clinical studies have been undertaken in order to evaluate the efficacy of IGF-1 in a range of diseases. IGF-1 has been administered to patients with type-II diabetes, to cachectic patients, to patients with ischemic damage at the neuronal, myocardial or renal level, and has been proposed for repairing and regenerating tissues (W.L. Lowe, Insulin-like growth factors, Scientific American Science and Medicine p. 62, March 1996).

From the above, it is clear that the administration of IGF-1 may be therapeutically useful in various morbid conditions. Examples of diseases or disorders which may be prevented, cured or improved by the administration of IGF-1 include neuropathies of the optic nerve

and of the olfactory nerve, neuralgia of the trigeminal nerve, Bell's paralysis, amyotrophic lateral sclerosis and other motor neuron diseases, degeneration of the retina, osteoporosis, arthropathy, arthritis, cervical spondylosis and hernia of the intervertebral discs, clinical syndromes of reduced height, cachexia, acute or chronic hepatic necrosis, Turner's syndrome, sarcopenia, growth hormone insensitivity syndromes, diabetes, obesity, asthenia in general and in particular myasthenia and heart asthenia, immunodeficiencies and reperfusion injuries. IGF-1 moreover appears to be useful for the cicatrization of wounds, the healing of ulcers, the treatment of burns, tissue regeneration in general and in particular that of cutaneous, intestinal and hepatic tissue, and the formation of dentine.

Unfortunately, the administration of IGF-1 in man brings about undesirable effects such as oedema, pain in the temporomandibular joint and arthralgia. These symptoms are such as to prevent the administration of IGF-1 from being recommended or are responsible for interrupting the treatment. It is therefore necessary to find novel substances which are capable of inducing the production of IGF-1.

According to the present invention, the administration of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine or pharmacologically acceptable salts thereof is capable of inducing the production of IGF-1 without the undesirable effects produced by the administration of exogenous IGF-1.

In the description which follows, the expression pharmacologically acceptable salt of L-acetylcarnitine, of L-isovalerylcarnitine or of L-propionylcarnitine is understood to refer to any salt of the above with an acid which does not give rise to undesirable toxicity or side-effects. Such acids are well known to pharmacologists and to experts in the pharmaceutical field.

Non-limiting examples of such salts are: chloride; bromide; iodide; aspartate, in particular hydrogen aspartate; citrate, in particular

hydrogen citrate; tartrate; phosphate, in particular hydrogen phosphate; fumarate, in particular hydrogen fumarate; glycerophosphate, glucose phosphate; lactate; maleate, in particular hydrogen maleate; orotate; oxalate, in particular hydrogen oxalate; sulphate, in particular hydrogen sulphate; trichloroacetate, trifluoroacetate and methanesulphonate.

In the description which follows, for the purposes of brevity and for ease of explanation, reference will be made only to L-acetylcarnitine, it being understood that the description given applies also to the above-mentioned L-isovalerylcarnitine and L-propionylcarnitine and to pharmacologically acceptable salts thereof.

Therapeutic uses of L-acetylcarnitine, L-isovalerylcarnitine and L-propionylcarnitine for the therapeutic treatment of myocardial arrhythmia and ischemia, peripheral functional vasculopathy of the arteries, senile dementia and peripheral neuropathies are already previously known. However, there is no correlation between these known therapeutic uses and the subject of the present invention.

It has now been found, surprisingly, that L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine or pharmaceutically acceptable salts thereof are capable of increasing the levels of IGF-1 in human biological fluids. It should be emphasized that, on the basis of extensive supporting scientific literature, the mechanism of action of L-acetylcarnitine has been focused at the metabolic level, more specifically demonstrating a protective action with respect to the mitochondria, whereas the present invention demonstrates an action mediated by the production of IGF-1.

In one embodiment of the present invention, the L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine or pharmaceutically acceptable salts thereof are administered in combination with vasodilatory, vascular, endocrinological, immunological, cytostatic, immunomodulatory, anti-inflammatory or cortisone pharmaceutical

products, IGF-1, IGF-1 binding proteins, growth hormones and other cell growth factors such as, for example, epidermal growth factor, and erythropoietin.

The examples which follow are for the purpose of illustrating the invention and should in no way be understood as implying a limitation in the scope thereof.

Example 1

13 individuals infected with HIV were enrolled. Blood was taken before and after treatment with L-acetylcarnitine orally at a dosage of 3 g/day for 8 weeks. The levels of IGF-1 were measured using a kit supplied by Amersham Italia s.r.l., Milan, and the results were expressed as ng of IGF-1/100 µl of serum.

Table 1

Patient #	Before	After
1	0.03	4.16
2	0.03	5
3	0.03	0.06
4	0.02	5
5	0.02	0.05
6	0.04	3.25
7	0.25	5
8	0.02	0.03
9	0.1	5
10	0.07	5
11	0.03	5
12	0.16	3.49
13	0.03	0.18
AVERAGE	0.06	3.17
Standard deviation	0.07	2.22
Standard error	0.02	0.62
Student test		0.0002

It is known that individuals infected with HIV can have variable levels of IGF-1 in their serum. The experiments reported here demonstrated that the oral administration of L-acetylcarnitine increases the levels of IGF-1 in peripheral blood.

Example 2

Four patients aged above 70 and with healthy dispositions were treated with 2 grams/day of L-acetylcarnitine parenterally for 7 days. The results of the doses of IGF-1 before and after the treatment are reported in Table 2.

Table 2

Patient #	Before	After
1	0.01	2.1
2	0.02	3.6
3	0.05	1.8
4	0.03	3.8
AVERAGE	0.03	2.83
Standard deviation	0.02	1.02
Standard error	0.008	0.51
Student test		0.01

Claims

1. Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine or pharmacologically acceptable salts thereof for producing a pharmaceutical product for increasing the levels of IGF-1 for the therapeutic treatment or prophylaxis of cytological disorders or diseases related to IGF-1.
2. Use according to Claim 1, for producing a pharmaceutical product for the therapeutic treatment or prophylaxis of neuropathies of the optic nerve and of the olfactory nerve, neuralgia of the trigeminal nerve, Bell's paralysis, amyotrophic lateral sclerosis and other motor neuron diseases, degeneration of the retina, osteoporosis, arthropathy, arthritis, cervical spondylosis and hernia of the intervertebral discs, clinical syndromes of reduced height, cachexia and acute or chronic hepatic necrosis, Turner's syndrome, sarcopenia, growth hormone insensitivity syndromes, diabetes, obesity, asthenia in general and in particular myasthenia and heart asthenia, immunodeficiencies and reperfusion injuries, and for the cicatrization of wounds, the healing of ulcers, the treatment of burns, tissue regeneration in general and in particular that of cutaneous, intestinal and hepatic tissue, and the formation of dentine.
3. Use according to Claim 1 or 2, in which the L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine or pharmacologically acceptable salts thereof are administered in combination with vasodilatory, vascular, endocrinological, immunological, cytostatic, immunomodulatory, anti-inflammatory or cortisone pharmaceutical products, IGF-1, IGF-1 binding proteins, growth hormones and other cell growth factors [epidermal growth factor, and erythropoietin].
4. Use according to any one of the preceding claims, in which the active principle is L-acetylcarnitine.

5. Use according to any one of Claims 1 to 3, in which the active principle is L-isovalerylcarnitine.
6. Use according to any one of Claims 1 to 3, in which the active principle is L-propionylcarnitine.
7. Pharmaceutical composition which may be administered orally, parenterally, nasally or topically for increasing the levels of IGF-1 for the therapeutic treatment or prophylaxis of cytological disorders or diseases related to IGF-1, this composition comprising, as active principle, an amount of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine or of pharmacologically acceptable salts thereof which is effective in increasing the levels of IGF-1, and at least one pharmacologically acceptable excipient.
8. Pharmaceutical composition according to Claim 7, for the therapeutic treatment or prophylaxis of neuropathies of the optic nerve and of the olfactory nerve, neuralgia of the trigeminal nerve, Bell's paralysis, amyotrophic lateral sclerosis and other motor neuron diseases, degeneration of the retina, osteoporosis, arthropathy, arthritis, cervical spondylosis and hernia of the intervertebral discs, clinical syndromes of reduced height, cachexia and acute or chronic hepatic necrosis, Turner's syndrome, sarcopenia, growth hormone insensitivity syndromes, diabetes, obesity, asthenia in general and in particular myasthenia and heart asthenia, immunodeficiencies and reperfusion injuries, and for the cicatrization of wounds, the healing of ulcers, the treatment of burns, tissue regeneration in general and in particular that of cutaneous, intestinal and hepatic tissue, and the formation of dentine, this composition comprising, as active principle, an amount of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine or of pharmacologically acceptable salts thereof which is effective in increasing the levels of IGF-1, and at least one pharmacologically acceptable excipient.

9. Composition according to Claim 7 or 8, which is suitable for the oral, parenteral, nasal or topical administration of 0.01 mg-15 g per day of active principle.

10. Composition according to Claim 7 or 8, which is suitable for the oral, parenteral, nasal or topical administration of 0.1 mg - 10 g per day of active principle.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IT 97/00113

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 516 594 A (SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE SPA) 2 December 1992 see the whole document ---	1,2,5, 7-10
X	WO 95 00137 A (BERNARDINI) 5 January 1995 see the whole document ---	1,2,4, 7-10
X	W.G. SANNITA ET AL.: "Effects of intravenous L-acetylcarnitine on retinal oscillatory potentials." DOC. OPHTHALMOL., vol. 70, 1988, pages 89-96, XP002042648 see the whole document ---	1,2,4,7, 8
-/-		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

6 October 1997

Date of mailing of the international search report

15.10.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Klaver, T

INTERNATIONAL SEARCH REPORT

Intern. Application No
PCT/IT 97/00113

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	D.J. PAULSON ET AL.: "Protection of the ischaemic myocardium by L-propionylcarnitine: effects on the recovery of cardiac output after ischaemia and reperfusion, carnitine transport, and fatty acid oxidation." CARDIOVASC. RES., vol. 20, no. 7, 1986, pages 536-541, XP002042649 * abstract *	1,2,4, 6-10
X	A.J. LIEDTKE ET AL.: "Effects of L-propionylcarnitine on mechanical recovery during reflow in intact hearts." AM. J. PHYSIOL., vol. 255, no. 1 pt 2, 1988, pages h169-h176, XP002042650 * abstract *	1,2,6-10
X	C. ADEMBRI ET AL.: "Ischemia-reperfusion of human skeletal muscle during aortoiliac surgery: effects of acetylcarnitine." HISTOL. HISTOPATHOL., vol. 9, no. 4, 1994, pages 683-690, XP002042651 * abstract *	1,2,4, 7-10
X	J.A. LEIPÄLÄ ET AL.: "Protection of the reperfused heart by L-propionylcarnitine." J. APPLIED PHYSIOL., vol. 71, no. 4, 1991, pages 1518-1528, XP002042652 * abstract *	1,2,6-10
A	WO 94 01101 A (SHUG) 20 January 1994	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IT 97/00113

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 516594 A	02-12-92	IT 1245699 B CA 2069520 A JP 5148200 A US 5227518 A	14-10-94 30-11-92 15-06-93 13-07-93
WO 9500137 A	05-01-95	AU 6922994 A CA 2142725 A WO 9500138 A US 5656628 A	17-01-95 05-01-95 05-01-95 12-08-97
WO 9401101 A	20-01-94	US 5240961 A AU 4646693 A	31-08-93 31-01-94